Skip to content
AnalystLens

Cencora, Inc. 8-K Report, Material Agreement (Jan 16, 2026)

Reports
Material Agreements·Financial Events·Exhibits & Filings
Filing Date
Filed January 16, 2026
Period End
January 12, 2026
Security
COR
In the record · 2016–202610-K1010-Q338-K184

COR filed 10 annual reports (10-K), 33 quarterly reports (10-Q) and 184 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Mar ’19Mar ’19
  2. Deal closed8-K · Jun ’21Jun ’21
  3. Leadership change8-K · Jan ’23Jan ’23
  4. Material agreement8-K · Feb ’25Feb ’25

01—Abstract

Summary

Summary of the 8-K filed January 16, 2026. Cited figures are marked; the original filing is the authoritative source.

Cencora, Inc. (COR) has filed an 8-K detailing significant financing activities to support its previously announced acquisition of the majority of the outstanding equity interests in OneOncology.

The company has entered into a $1.5 billiona Term Credit Agreement and a $3.0 billion 364-Day Term Credit Facility, totaling $4.5 billion in new debt. These facilities will fund a portion of the acquisition consideration, repay existing OneOncology debt, and cover related fees and expenses.

The new debt structure replaces previously secured bridge financing commitments. This move underscores Cencora's commitment to completing the OneOncology acquisition, a strategic initiative that is expected to significantly impact the company's operations and market position.

02—Key points

Key Highlights

  1. Cencora has secured $4.5 billion in new debt financing through a $1.5 billion Term Credit Agreement and a $3.0 billion 364-Day Term Credit Facility to fund the OneOncology acquisition.
  2. The new financing replaces $4.5 billion in previously announced bridge financing commitments.
  3. The Term Credit Agreement has two tranches: $500 million maturing in two years and $1.0 billion maturing in three years from their draw dates.
  4. The 364-Day Term Credit Facility matures 364 days from its draw date.
  5. Interest rates for these facilities are tied to SOFR or alternate base rates, plus an applicable margin based on Cencora's public debt ratings, ranging from 0 to 125 basis points.
  6. The company has also amended its existing Revolving Credit Facility, increasing the aggregate commitments by $1.0 billion to $5.5 billion.
  7. Key financial covenants include a leverage ratio not to exceed 4.00 to 1.00, with a potential increase to 4.50 to 1.00 upon a material acquisition.

03—Questions

Frequently Asked Questions

  1. What is the primary purpose of the new financing arrangements?

    The primary purpose of the new financing is to fund a portion of the consideration for Cencora's previously announced acquisition of the majority of the outstanding equity interests in OneOncology, as well as to repay existing debt of OneOncology and cover associated fees and expenses.

  2. How much total debt has Cencora secured for the acquisition?

    Cencora has secured a total of $4.5 billion in new debt financing through the Term Credit Agreement ($1.5 billion) and the 364-Day Term Credit Facility ($3.0 billion).

  3. What is the difference between the Term Credit Agreement and the 364-Day Term Credit Facility?

    The Term Credit Agreement provides a $1.5 billion facility with loans maturing either two or three years after their respective draw dates. The 364-Day Term Credit Facility is for $3.0 billion and matures 364 days after its draw date. Both are senior unsecured facilities, but they differ in maturity and size.

  4. What impact does this have on Cencora's existing credit facilities?

    Cencora has amended its Amended and Restated Credit Agreement to increase its revolving credit facility by $1.0 billion, bringing the total commitments to $5.5 billion. This enhanced revolving facility provides additional liquidity. Furthermore, the new term loan and 364-day facility effectively replace $4.5 billion in previously committed bridge financing.

04—Continue

← View all 8-K filings